Schenell Biopharmaceutical jumps into biosimilars

Schenell Biopharmaceutical Inc. is jumping into a blue ocean for newer versions of innovator biopharmaceutical products, biosimilars, following an agreement with Aprogen Co. to take over all marketing rights of biosimilar products, such as Rituxan and Remicade.

Schenell said in a regulatory filing on January 11 that the company will conduct a local clinical study on Rituxan after its affilia...